



Recent Developments New MA for Antimicrobials since 00 • 95 % Generics • New Claims • New active Ingredients • New Formulations • New Classes: ?


Recent Developments Generics Valuable development to harmonise EU markets Problems regarding harmonisation of claims Is this true innovation?



























New Actives? No independent basic Research for Antimicrobials in Animal Health: Remainings from human R&D Also applies for currently used Classes: FQ, Ceph, Macrolides, Tetracyclines Risk-Benefit Assessment should also address the potential Consequences regarding future Innovation in such Area: Success will trigger Investment! Non-Approval will discourage all!

We believe: • Need for new, highly efficacious Antimicrobials for Animal Health, both pets and food producing species • Risk/Benefit assessment of industry currently not very positive: ↓ investment • Unlikely to invest in new Classes • Unlikely to invest in Classes, where such

encourages Investors

Guidance has created further Hurdles for MA

• The Guidance produced may not be, what

We propose: Broad political support to improve husbandry Avoid misuse of AM (see last AVC presentation) Invest in training farmers/vets for responsible use of AM Support the development of new Classes by Reducing hurdles to obtain MA Providing clarity to avoid spoiling money Society needs new Classes to treat new (resistant) organisms, support secure and safe food

